IMPLEMENTING PATIENTS' COMPETENCE IN ORAL EBC THERAPY PERSISTENCE

Inclusion Criteria: * Women age 18 or older at time of ICF signature * Patients with HRpos/HER2neg early breast cancer who are treated with oral, commercially available prescribed abemaciclib in combination with endocrine therapy. Patients can be included if abemaciclib therapy was started no more than 28 days ago * Patients treated with abemaciclib according to the SmPC and each center´s medical practice * Informed consent given prior to the starting study activities Exclusion Criteria: * Women who are pregnant or lactating * Patients with contraindications against abemaciclib according to the current SmPC * Patients who are not eligible for the study due to severe comorbidities, unavailability or any other relevant reason according to the treating physician